{'fraction_non_alphanumeric': 0.01583710407239819, 'fraction_numerical': 0.0, 'mean_word_length': 5.230046948356808, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Recognition of Dementia Biomarkers With Deep Finer-DBN

The treatment of neurodegenerative diseases is expensive, and long-term treatment makes families bear a heavy burden. Accumulating evidence suggests that the high conversion rate can possibly be reduced if clinical interventions are applied at the early stage of brain diseases. Thus, a variety of deep learning methods are utilized to recognize the early stages of neurodegenerative diseases for clinical intervention and treatment. However, most existing methods have ignored the issue of sample imbalance, which often makes it difficult to train an effective model due to lack of a large number of negative samples. To address this problem, we propose a two-stage method, which is used to learn the compression and recover rules of normal subjects so that potential negative samples can be detected. The experimental results show that the proposed method can not only obtain a superb recognition result, but also give an explanation that conforms to the physiological mechanism. Most importantly, the deep learning model does not need to be retrained for each type of disease, which can be widely applied to the diagnosis of various brain diseases. Furthermore, this research could have great potential in understanding regional dysfunction of various brain diseases.